GENB Stock Generate Biomedicines (GENB, $17.72) was a top quarterly gainer, rising +32.83%
at Tickeron.com
Loading...
Generate Biomedicines (GENB, $17.72) was one of top quarterly gainers, jumping +3 to $17.72 per share. A.I.dvisor analyzed 595 stocks in the Biotechnology Industry over the last three months, and discovered that of them (7) charted an Uptrend while of them (2) trended down.
Momentum Indicator for GENB turns positive, indicating new upward trend
GENB saw its Momentum Indicator move above the 0 level on September 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator turned positive. In 13 of the 13 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GENB just turned positive on September 18, 2026. Looking at past instances where GENB's MACD turned positive, the stock continued to rise in 3 of 3 cases over the following month. The odds of a continued upward trend are 90%.
The 10-day moving average for GENB crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +1.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where GENB advanced for three days, in 27 of 28 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 20 of 20 cases where GENB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for GENB moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator moved out of overbought territory. In 2 of the 4 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
GENB broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. GENB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.824) is normal, around the industry mean (25.951). P/E Ratio (0.000) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (75.758) is also within normal values, averaging (436.793).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.